Meglimine Sodium Succinate for Correction of Metabolic Acidosis in Critically Ill Patients
Status:
Recruiting
Trial end date:
2022-09-01
Target enrollment:
Participant gender:
Summary
An acid-base imbalance, called metabolic acidosis (acid-base disorder lasting from several
minutes to several days, caused by a decrease in serum bicarbonate ion (HCO3) concentration),
is often observed in critically ill patients with various underlying diseases. Metabolic
acidosis has a negative impact on the cardiovascular, respiratory, digestive, nervous,
excretory, hematological, endocrine, musculoskeletal and immune systems and is associated
with unfavourable outcomes. Reamberin® is a solution of disubstituted sodium salt of succinic
acid, which has an alkaline reaction and succinate is capable to integrate into the Krebs
cycle and restore energy metabolism in the cell. The aim of the present study is to evaluate
the efficacy and safety of meglumine sodium succinate at a dose of 500 to 3000 ml in
critically ill patients with metabolic acidosis and choose the optimal volume of its solution
for the correction of metabolic acidosis in critically ill patients.
Phase:
Phase 2
Details
Lead Sponsor:
POLYSAN Scientific & Technological Pharmaceutical Company